Skip to main content
Premium Trial:

Request an Annual Quote

Caris to Provide Biomarker Discovery, Molecular Testing for Incyte Oncology Drug Development

NEW YORK – Caris Life Sciences said Tuesday that it has entered a strategic research partnership with Wilmington, Delaware-based Incyte to augment precision medicine approaches for the drugmaker's oncology pipeline.

Under the terms of the agreement, Incyte will use Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for two oncology drug programs, with the option to expand to a total of four. The specific programs were not named.

Incyte will also use Caris' biomarker-driven patient selection for clinical trials that result from these efforts, and the company will test enrolled patients using its comprehensive tissue and liquid molecular profiling assays. The firm said the deal also includes options to partner on developing companion diagnostics.

"Incyte is committed to identifying new treatments for cancer patients using approaches exploring both single agents and combinations of targeted therapies and immunotherapies in areas of high unmet medical need," Jeff Jackson, Incyte's VP of translational sciences, said in a statement.

Financial terms were not disclosed.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.